» Articles » PMID: 27911942

Persistent Morbillivirus Infection Leads to Altered Cortactin Distribution in Histiocytic Sarcoma Cells with Decreased Cellular Migration Capacity

Overview
Journal PLoS One
Date 2016 Dec 3
PMID 27911942
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Histiocytic sarcomas represent rare but fatal neoplasms in humans. Based on the absence of a commercially available human histiocytic sarcoma cell line the frequently affected dog displays a suitable translational model. Canine distemper virus, closely related to measles virus, is a highly promising candidate for oncolytic virotherapy. Therapeutic failures in patients are mostly associated with tumour invasion and metastasis often induced by misdirected cytoskeletal protein activities. Thus, the impact of persistent canine distemper virus infection on the cytoskeletal protein cortactin, which is frequently overexpressed in human cancers with poor prognosis, was investigated in vitro in a canine histiocytic sarcoma cell line (DH82). Though phagocytic activity, proliferation and apoptotic rate were unaltered, a significantly reduced migration activity compared to controls (6 hours and 1 day after seeding) accompanied by a decreased number of cortactin mRNA transcripts (1 day) was detected. Furthermore, persistently canine distemper virus infected DH82 cells showed a predominant diffuse intracytoplasmic cortactin distribution at 6 hours and 1 day compared to controls with a prominent membranous expression pattern (p ≤ 0.05). Summarized, persistent canine distemper virus infection induces reduced tumour cell migration associated with an altered intracellular cortactin distribution, indicating cytoskeletal changes as one of the major pathways of virus-associated inhibition of tumour spread.

Citing Articles

Functional Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF) Delivered by Canine Histiocytic Sarcoma Cells Persistently Infected with Engineered Attenuated Canine Distemper Virus.

Marek K, Armando F, Asawapattanakul T, Nippold V, Plattet P, Gerold G Pathogens. 2023; 12(7).

PMID: 37513724 PMC: 10385001. DOI: 10.3390/pathogens12070877.


Respiratory syncytial virus disrupts the airway epithelial barrier by decreasing cortactin and destabilizing F-actin.

Gao N, Raduka A, Rezaee F J Cell Sci. 2022; 135(16).

PMID: 35848790 PMC: 9481929. DOI: 10.1242/jcs.259871.


Persistent Infection of a Canine Histiocytic Sarcoma Cell Line with Attenuated Canine Distemper Virus Expressing Vasostatin or Granulocyte-Macrophage Colony-Stimulating Factor.

Marek K, Armando F, Nippold V, Rohn K, Plattet P, Brogden G Int J Mol Sci. 2022; 23(11).

PMID: 35682834 PMC: 9181094. DOI: 10.3390/ijms23116156.


Overcoming the Barrier of the Respiratory Epithelium during Canine Distemper Virus Infection.

Shin D, Chludzinski E, Wu N, Peng J, Ciurkiewicz M, Sawatsky B mBio. 2022; 13(1):e0304321.

PMID: 35038920 PMC: 8764546. DOI: 10.1128/mbio.03043-21.


Intratumoral Canine Distemper Virus Infection Inhibits Tumor Growth by Modulation of the Tumor Microenvironment in a Murine Xenograft Model of Canine Histiocytic Sarcoma.

Armando F, Fayyad A, Arms S, Barthel Y, Schaudien D, Rohn K Int J Mol Sci. 2021; 22(7).

PMID: 33808256 PMC: 8037597. DOI: 10.3390/ijms22073578.


References
1.
Klauschies F, Gutzkow T, Hinkelmann S, von Messling V, Vaske B, Herrler G . Viral infectivity and intracellular distribution of matrix (M) protein of canine distemper virus are affected by actin filaments. Arch Virol. 2010; 155(9):1503-8. DOI: 10.1007/s00705-010-0737-6. View

2.
Howard J, Eckert B, Bourguignon L . Comparison of cytoskeletal organization in canine distemper virus-infected and uninfected cells. J Gen Virol. 1983; 64 (Pt 11):2379-85. DOI: 10.1099/0022-1317-64-11-2379. View

3.
Seehusen F, Orlando E, Wewetzer K, Baumgartner W . Vimentin-positive astrocytes in canine distemper: a target for canine distemper virus especially in chronic demyelinating lesions?. Acta Neuropathol. 2007; 114(6):597-608. DOI: 10.1007/s00401-007-0307-5. View

4.
Schlick K, Aigelsreiter A, Pichler M, Reitter S, Neumeister P, Hoefler G . Histiocytic sarcoma - targeted therapy: novel therapeutic options? A series of 4 cases. Onkologie. 2012; 35(7-8):447-50. DOI: 10.1159/000340066. View

5.
Eckert M, Yang J . Targeting invadopodia to block breast cancer metastasis. Oncotarget. 2011; 2(7):562-8. PMC: 3248174. DOI: 10.18632/oncotarget.301. View